Fueling our efforts in the education arena
In 2010 the 3-21 Foundation began its work in the field of cognition with a comprehensive investigation of the state of the art for drugs and supplements for cognitive enhancement in Down syndrome. This investigation built on the earlier work of two of its Directors in advising and investing in an early stage neurobiology firm developing a drug for Down syndrome cognition.
The 3-21 Foundation also participated in the first international scientific symposium on cognition in Down syndrome in 2013, hosted by the Global Down Syndrome Foundation and other leading Down syndrome research institutions and funders. In 2015, the 3-21 Foundation received a grant allowing us to expand our efforts in cognition by making targeted direct seed investments.